V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 300006383 | 300004474 | 1.74 | 70.7 | null | 2014-12-06 | 2014-12-12 | CARBOPLATIN + RT | N | N | 300016263 | CAPECITABINE |
| 300006384 | 300006851 | 1.49 | 46.5 | Palliative (P) | null | 2014-05-03 | Carbo F | N | N | 300016265 | GEMCARBO |
| 300006387 | 300006853 | 1.51 | 55.6 | null | 2013-05-21 | 2013-05-21 | CAPECITABINE + RT | 2 | Y | 300016274 | CETUXIMAB |
| 300006388 | 300006853 | null | null | Curative (C) | 2016-10-06 | 2016-10-21 | Carboplatin + Etoposide iv&po | 02 | N | 300016274 | CISPLATIN + FLUOROURACIL |
| 300006389 | 300004479 | 1.54 | 71.6 | Neo-adjuvant (N) | 2014-06-26 | 2014-06-26 | VAC | Y | N | 300016277 | GEMCARBO |
| 300006390 | 300004479 | null | 65.9 | Neo-adjuvant (N) | 2016-08-08 | 2016-08-20 | TEYSUNO | N | N | 300016277 | CARBOPLATIN + CETUXIMAB + FU |
| 300006391 | 300004480 | 1.72 | 75.3 | Curative (C) | 2015-01-18 | 2015-01-27 | CETUXIMAB + RT | N | Y | 300016282 | CETUXIMAB |
| 300006392 | 300004481 | 1.8 | 84.5 | Curative (C) | 2016-12-17 | 2016-12-28 | NAB PACLITAXEL | N | N | 300016288 | TOPOTECAN |
| 300006393 | 300004483 | 1.54 | 79.9 | Palliative (P) | 2017-06-09 | 2017-06-22 | CISPLATIN + FLUOROURACIL | N | N | 300016288 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 300006394 | 300004484 | 1.63 | 75 | Curative (C) | 2016-07-09 | 2016-07-10 | Oxaliplatin + Modified de Gramont | 2 | N | 300016300 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 300006395 | 300004485 | 1.86 | 79.3 | Curative (C) | 2016-01-28 | 2016-02-04 | Cisplatin +Fluorouracil (3 wk) | 02 | Y | 300016301 | CARBOPLATIN |
| 300006396 | 300004485 | null | 40 | Curative (C) | 2016-09-30 | 2016-11-12 | Cetuximab + Radiotherapy Maint | N | Y | 300016301 | CARBOPLATIN |
| 300006397 | 300004485 | 1.58 | 87 | Curative (C) | 2014-03-21 | 2014-04-07 | Cisplatin | 02 | Y | 300016301 | CARBOPLATIN |
| 300006398 | 300004485 | 1.63 | 76.3 | Curative (C) | 2017-07-16 | 2017-08-04 | CISPLATIN + FLUOROURACIL | 02 | null | 300016301 | OXALIPLATIN + MDG |
| 300006399 | 300004485 | 1.67 | 88.1 | Curative (C) | 2017-06-07 | 2017-07-08 | CISPLATIN + FLUOROURACIL | 02 | N | 300016301 | CETUXIMAB |
| 300006400 | 300004486 | 1.85 | 100.65 | Adjuvant (A) | 2015-09-25 | 2015-09-30 | Cisplatin + Fluorouracil + RT 5day | 02 | Y | 300016330 | CETUXIMAB + RT |
| 300006401 | 300004487 | 1.49 | 49.6 | Palliative (P) | 2013-12-11 | 2014-03-31 | Irinotecan + Modified De Gramont | N | N | 300016337 | TOPOTECAN |
| 300006402 | 300004488 | 1.85 | 52 | Palliative (P) | 2016-02-25 | 2016-02-25 | Docetaxel 75mg/m2 (21 day) | N | N | 300016341 | IPILIMUMAB + NIVOLUMAB |
| 300006403 | 300004489 | 1.65 | null | Neo-adjuvant (N) | null | 2014-12-25 | Trial Unspecified | N | N | 300016348 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 300006404 | 300006862 | 1.6 | 58.5 | Neo-adjuvant (N) | 2014-09-09 | 2014-09-11 | ESPAC-4 TRIAL | 02 | null | 300016352 | RITUXIMAB |
| 300006405 | 300004493 | 0 | null | Neo-adjuvant (N) | 2015-11-22 | 2015-10-07 | Capecitabine | 02 | null | 300016354 | FLUOROURACIL |
| 300006406 | 300004494 | null | 58.75 | Curative (C) | 2014-05-27 | 2014-06-13 | CAPECITABINE + RT | 02 | Y | 300016354 | CISPLATIN + FLUOROURACIL + RT |
| 300006407 | 300004495 | null | 59.8 | Palliative (P) | 2017-03-26 | 2017-04-02 | null | 02 | N | 300016364 | IRINOTECAN + MDG |
| 300006408 | 300004497 | 1.62 | 58.6 | Curative (C) | 2013-06-01 | 2013-06-28 | PEMBROLIZUMAB | 02 | null | 300016381 | OXALIPLATIN + MDG |
| 300006409 | 300004497 | 1.69 | 72.1 | Palliative (P) | 2014-04-19 | 2014-05-05 | null | N | Y | 300016381 | CETUXIMAB + RT |
| 300006410 | 300004498 | 1.55 | 66.7 | Curative (C) | 2016-12-14 | 2017-01-10 | Cisplatin | N | Y | 300016386 | CARBOPLATIN + CETUXIMAB + FU |
| 300006411 | 300004498 | 1.6 | 66 | Palliative (P) | 2013-09-18 | 2013-09-18 | Carboplatin AUC 6 - 10 | N | N | 300016386 | CISPLATIN + FLUOROURACIL |
| 300006412 | 300004501 | 1.95 | 93 | Curative (C) | 2015-06-11 | 2015-06-20 | Trial Unspecified | 02 | N | 300016399 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 300006413 | 300004502 | 1.7 | 71.4 | Curative (C) | 2013-10-30 | 2013-11-02 | DE-ESCALATE TRIAL | 02 | Y | 300016401 | CETUXIMAB |
| 300006414 | 300004503 | 1.75 | 61.15 | Curative (C) | 2013-10-01 | 2013-10-08 | CISPLATIN + FLUOROURACIL | 2 | Y | 300016404 | CISPLATIN + FLUOROURACIL + RT |
| 300006415 | 300004504 | 1.63 | 82.4 | Curative (C) | 2015-10-13 | 2015-11-21 | Carboplatin AUC 2 - 5 | N | Y | 300016413 | CAPECITABINE + RT |
| 300006416 | 300004507 | 1.75 | 44.3 | Neo-adjuvant (N) | 2018-03-25 | 2018-04-02 | Capecitabine | 02 | N | 300016413 | CHOP R |
| 300006417 | 300004507 | 1.59 | 69.2 | Palliative (P) | null | 2015-04-23 | NIVOLUMAB | N | N | 300016413 | CAPECITABINE |
| 300006418 | 300004508 | 1.72 | 65 | Curative (C) | 2017-05-28 | 2017-06-18 | Cetuximab+Cisplatin+FU (> Cycle 2) | N | Y | 300016438 | CARBOPLATIN + RT |
| 300006420 | 300004510 | null | 49.55 | Curative (C) | 2013-04-18 | 2013-06-25 | Cetuximab + Radiotherapy Maint | N | N | 300016451 | OXALIPLATIN + MDG |
| 300006421 | 300004515 | 1.52 | 55.8 | Palliative (P) | 2014-09-20 | 2014-10-16 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 300016455 | CARBOPLATIN + RT |
| 300006422 | 300004517 | 1.67 | null | Curative (C) | 2017-09-20 | 2017-10-09 | GemCarbo Days 1+8 | null | null | 300016461 | CARBOPLATIN |
| 300006423 | 300004518 | null | null | Palliative (P) | 2014-06-05 | 2014-06-13 | CAPECITABINE + OXALIPLATIN | N | N | 300016465 | UKALL XII |
| 300006425 | 300004520 | null | 88.6 | Neo-adjuvant (N) | 2015-08-08 | 2015-11-17 | Capecitabine + Oxaliplatin 21day | 02 | N | 300016477 | CISPLATIN |
| 300006426 | 300004521 | 1.63 | 62 | Palliative (P) | 2016-10-20 | 2016-10-31 | CARBOPLATIN + PACLITAXEL | N | N | 300016483 | CISPLATIN + FLUOROURACIL |
| 300006427 | 300004523 | 1.74 | 65 | Palliative (P) | 2014-04-15 | 2014-04-25 | Fluorouricil + Folonic Acid (MdG) | 02 | N | 300016503 | TRIAL |
| 300006428 | 300004524 | 1.81 | 109.8 | Adjuvant (A) | 2014-02-06 | 2014-02-25 | ESPAC-4 TRIAL | 2 | null | 300016504 | CISPLATIN |
| 300006429 | 300004524 | 1.67 | 98 | Palliative (P) | 2015-01-15 | 2015-02-16 | Cisplatin +Fluorouracil (3 wk) | N | N | 300016504 | MITOTANE |
| 300006430 | 300004525 | null | null | Palliative (P) | 2013-04-12 | 2013-04-12 | CETUXIMAB + CISPLATIN + FU | N | N | 300016508 | CETUXIMAB |
| 300006431 | 300004525 | 1.9 | 60 | Curative (C) | 2013-08-22 | 2013-09-06 | ESPAC-4 TRIAL | 02 | null | 300016508 | CHOP R + LIPOSOMAL DOX |
| 300006432 | 300004527 | 1.74 | 78.3 | Curative (C) | 2014-03-20 | 2014-03-24 | Cetuximab 7 day (>Cycle 2) | Y | Y | 300016513 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 300006433 | 300004527 | 1.66 | 66 | Palliative (P) | 2016-03-19 | 2016-03-19 | METROBIBF trial | 02 | null | 300016513 | CETUXIMAB + RT |
| 300006434 | 300004527 | 1.71 | 128 | Adjuvant (A) | 2013-06-16 | 2013-07-11 | NIVOLUMAB | N | N | 300016513 | IPILIMUMAB + NIVOLUMAB |
| 300006435 | 300004527 | 1.67 | 72.8 | Palliative (P) | 2014-01-04 | 2014-01-12 | Cytarabine intrathecal | N | N | 300016513 | CAPECITABINE + GEMCITABINE |
| 300006436 | 300004528 | 1.59 | 74.6 | Curative (C) | 2018-11-05 | 2018-11-14 | Oxaliplatin + Modified de Gramont | 2 | N | 300016545 | KESTREL TRIAL |